215. Tetralogy of Fallot Clinical trials / Disease details
Clinical trials : 18 / Drugs : 26 - (DrugBank : 14) / Drug target genes : 13 - Drug target pathways : 45
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05579964 (ClinicalTrials.gov) | October 10, 2022 | 11/10/2022 | The Role of Dexmedetomidine as Myocardial Protector in Pediatric Cardiac Surgery Total Correction of Tetralogy of Fallot | The Role of Dexmedetomidine as Myocardial Protector in Pediatric Cardiac Surgery Total Correction of Tetralogy of Fallot | Congenital Heart Disease in Children;Cardiopulmonary Bypass;Tetralogy of Fallot | Drug: Dexmedetomidine Hcl 100 Mcg/mL Inj;Drug: Placebo | National Cardiovascular Center Harapan Kita Hospital Indonesia | NULL | Recruiting | 1 Month | 18 Years | All | 66 | Phase 2/Phase 3 | Indonesia |